Piper Sandler Begins Coverage on Cara Therapeutics (NASDAQ:TVRD)

Piper Sandler assumed coverage on shares of Cara Therapeutics (NASDAQ:TVRD) in a report released on Thursday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $78.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on TVRD. Oppenheimer assumed coverage on shares of Cara Therapeutics in a research note on Wednesday, May 21st. They issued an “outperform” rating and a $65.00 price objective for the company. Wall Street Zen raised shares of Cara Therapeutics to a “hold” rating in a research note on Saturday, May 24th.

Cara Therapeutics Trading Down 5.7%

Shares of TVRD opened at $24.62 on Thursday. Cara Therapeutics has a 1 year low of $8.13 and a 1 year high of $34.31.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.